The purpose of this study is to characterize the safety and efficacy in patients with
generalized anxiety disorder after short- (3 months) and long-term (6 months) use of
Pregabalin (Lyrica).
Number of Participants With Rebound Anxiety for Cohort 1 (Less Than 3-Month Last Visit)Number of Participants With Rebound Anxiety for Cohort 2 (3-Month Last Visit)
Number of Participants With Rebound Anxiety for Cohort 3 (6-Month Last Visit)
Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 1 (Less Than 3-Month Last Visit)
Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 2 (3-Month Last Visit)
Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 3 (6-Month Last Visit)
Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2
Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2
Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2
Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit)
Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit)
Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit)
Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2
Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2
Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2
Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit)
Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit)
Hamilton Anxiety Scale (HAM-A) Score for Cohort 3 (6-Month Last Visit)
Hamilton Anxiety Scale (HAM-A) Score for Period 1
Hamilton Anxiety Scale (HAM-A) Score for Period 2
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 12
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24
Clinical Global Impression - Severity (CGI-S) Score for Period 1
Clinical Global Impression - Severity (CGI-S) Score for Period 2
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 12
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 24
Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 1
Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 2
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Pfizer Investigational Site, Buenos Aires C1405BOA, Argentina
Pfizer Investigational Site, Buenos Aires C1428AQK, Argentina
Pfizer Investigational Site, Buenos Aires C1115AAJ, Argentina
Pfizer Investigational Site, Wien A-1010, Austria
Pfizer Investigational Site, Wien A-1090, Austria
Pfizer Investigational Site, San Jose, Costa Rica
Pfizer Investigational Site, San Jose 00000, Costa Rica
Pfizer Investigational Site, Rijeka 51000, Croatia
Pfizer Investigational Site, Split 21000, Croatia
Pfizer Investigational Site, Zagreb 10000, Croatia
Pfizer Investigational Site, Brno 602 00, Czech Republic
Pfizer Investigational Site, Ceske Budejovice 370 87, Czech Republic
Pfizer Investigational Site, Litomerice 412 01, Czech Republic
Pfizer Investigational Site, Lnare 387 42, Czech Republic
Pfizer Investigational Site, Melnik 276 01, Czech Republic
Pfizer Investigational Site, Praha 10- Strasnice 10000, Czech Republic
Pfizer Investigational Site, Praha 2 120 00, Czech Republic
Pfizer Investigational Site, Praha 6 160 00, Czech Republic
Pfizer Investigational Site, Strakonice 386 01, Czech Republic
Pfizer Investigational Site, Espoo 02650, Finland
Pfizer Investigational Site, HUS 00029, Finland
Pfizer Investigational Site, Joensuu 80100, Finland
Pfizer Investigational Site, Kuopio 70110, Finland
Pfizer Investigational Site, Seinajoki 60100, Finland
Pfizer Investigational Site, Turku 20100, Finland
Pfizer Investigational Site, Athens 11528, Greece
Pfizer Investigational Site, Surabaya, Indonesia
Pfizer Investigational Site, Kaunas 50185, Lithuania
Pfizer Investigational Site, Kaunas 50425, Lithuania
Pfizer Investigational Site, Klaipeda 94231, Lithuania
Pfizer Investigational Site, Vilnius 09112, Lithuania
Pfizer Investigational Site, Mexico D.F. 14269, Mexico
Pfizer Investigational Site, Khotkovo, Moscow region 142601, Russian Federation
Pfizer Investigational Site, Moscow 107076, Russian Federation
Pfizer Investigational Site, Moscow 125367, Russian Federation
Pfizer Investigational Site, Moscow 119021, Russian Federation
Pfizer Investigational Site, Moscow 115522, Russian Federation
Pfizer Investigational Site, St. Petersburg 192019, Russian Federation
Pfizer Investigational Site, Belgrade 11000, Serbia
Pfizer Investigational Site, Kragujevac 34000, Serbia
Pfizer Investigational Site, Ljubljana, Slovenia
Pfizer Investigational Site, Zamora 49021, Spain
Pfizer Investigational Site, Istanbul 34203, Turkey
Pfizer Investigational Site, Kocaeli 41380, Turkey
Pfizer Investigational Site, Ellisbridge, Ahmedabad 380 006, India
Pfizer Investigational Site, Tirupati, Andhra Pradesh 517 507, India
Pfizer Investigational Site, Langreo, Asturias 33900, Spain
Pfizer Investigational Site, Denpasar, Bali, Indonesia
Pfizer Investigational Site, La Plata, Buenos Aires B1904ADM, Argentina
Pfizer Investigational Site, Acapulco, Guerrero 39670, Mexico
Pfizer Investigational Site, Jakarta Selatan, Jakarta 10430, Indonesia
Pfizer Investigational Site, Jakarta, Jakarta Selatan, Indonesia
Pfizer Investigational Site, Zapopan, Jalisco 45170, Mexico
Pfizer Investigational Site, Mangalore, Karnataka 575001, India
Pfizer Investigational Site, Pune, Maharashtra 411 030, India
Pfizer Investigational Site, Lanus, Prov. de Buenos Aires B1824IBR, Argentina
Pfizer Investigational Site, Chennai, Tamil Nadu 600 003, India